{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-042489","form_type":"8-K12B","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.597942+00:00","generated_at":"2026-05-23T02:45:47.712057+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN","bullets":["Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.","Liminatus develops anti-CD47 monoclonal antibody IBA101 for advanced solid cancers including non-small cell lung cancer.","Leadership: CEO Chris Kim, CFO Scott Dam, CSO Byong C. Yoo.","Business Combination approved at Iris stockholders meeting on March 4, 2025.","Advisors: Holland & Knight for Iris, Loeb & Loeb for Liminatus, Raymond James."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-042489","json":"https://secwatch.observer/filing/0001104659-25-042489.json","markdown":"https://secwatch.observer/filing/0001104659-25-042489.md","text":"https://secwatch.observer/filing/0001104659-25-042489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925042489/0001104659-25-042489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925042489/tm2513514d1_8k12b.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:45:47.712057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}